Introduction
============

Hearing loss (HL) is the most frequent form of sensory impairment in humans, with approximately 1--2 in 1000 infants being born with a serious HL (https://[www.gov.uk/guidance/newborn-hearing-screening-programme-overview](www.gov.uk/guidance/newborn-hearing-screening-programme-overview)). Over 70% of prelingual HL cases can be classified as non-syndromic HL (NSHL), where the hearing deficit is the only sign ([@B1]). HL can be inherited as autosomal recessive, autosomal dominant, mitochondrial, X- and Y-linked. Autosomal recessive mode of inheritance (ARNSHL) makes up 80% of the NSHL cases. ARNSHL is highly heterogeneous, for which over 100 mapped loci are known. The autosomal recessive loci are called DFNB followed by a number corresponding to the order that the locus was first explained; DFNB1 to DFNB105 have been reported so far (<http://hereditaryhearingloss.org>). However, more than seventy different DFNB loci have been mapped for ARNSHL by homozygosity mapping, an effective method to locate genes causing ARNSHL in large consanguineous families ([@B2]).

The genetic etiology of ARNSHL in Iran has been studied by a number of independent studies with a special focus on the certain locus DFNB1 (*GJB2*), as the most common cause of HL all over the world ([@B3]). Variants in the *GJB2* (NM_004004.5) could explain the etiology of ARNSHL in 4% to 35% of patients from different origin, suggesting that GJB2 gene mutations account for a part of ARNSHL in Iran. ([@B4], [@B5]). On the other hand, Iran is a large country with many ethnic groups and high rate of the consanguineous marriages (38.6% on average) ([@B6]). Thus, mutations in certain loci may be increased within some ethnic groups ([@B7]). Therefore, population-specific studies are necessary to identify other common loci and to determine the etiology of ARNSHL based on ethnicity. Until now, little data is available on the contribution of some frequent loci among the Iranian ARNSHL; and have mostly focused on mixed populations from different provinces ([@B8]). Mutations in at least 40 genes have been explained to cause ARNSHL in Iran. However, the contribution of their mutations does not appear to occur at the same frequencies across different ethnic groups ([@B9]).

We applied the homozygosity mapping strategy to identify the relative contribution of 10 DFNB loci to ARNSHL in the studied cohort including 60 ARNSHL families, which were negative for *GJB2* mutations, from Isfahan and Hamedan provinces for the first time. This data could be applied to design a cheap and accurate panel for common genes causing ARNSHL in certain regions of Iran and would lead to affordable testing and improved management of HL ([@B10]).

Materials and Methods
=====================

Families and clinical evaluations
---------------------------------

Totally, 60 unrelated consanguineous families with 3 or more hearing impaired patients and negative for *GJB2* mutations were recruited from Isfahan and Hamedan provinces in the center and west of Iran in 2017.

The Ethics Committee of the Isfahan University of Medical Sciences approved this project. All family members signed informed written consent prior to recruitment. They met the following criteria: 1) confirmation of HL by Pure tone audiometry (PTA) from 250--8000 Hz 2) the autosomal recessive inheritance deduced through pedigree analysis 3) existence of three or more affected members within the pedigree. A complete clinical investigation was performed to exclude environmental exposures and to determine the presence of syndromic findings in each family.

DNA extraction
--------------

Genomic DNA was extracted using Prime Prep Genomic DNA Extraction kit from blood (GeNet Bio, Korea) according to the manufacturer's instruction. Qualitative and quantitative assessment of genomic DNA was checked using 1.2% agarose gel and Nanospec cube biophotometer (Nanolytik®, Dusseldorf, Germany).

SLINK analysis and selection of DFNB loci
-----------------------------------------

Power of the pedigrees for linkage analysis was simulated by calculating SLINK, using FastSLink (ver.2.51) option of Easy linkage plus version 5.05 software to predict the potential LOD score in a given family ([@B11]). Based on the literature review of the most frequent loci, both globally and regionally, 10 loci were selected for screening. Screening sort tandem repeat (STR) markers were selected based on their physical distance found at NCBI UniSTS and NCBI Map Viewer (<http://www.ncbi.nlm.nih.gov>). Primers for STR markers of each locus were mostly obtained through the Probe database (<https://www.ncbi.nlm.nih.gov/probe>). STR markers of each locus and their primer sequences are listed in [Table 1](#T1){ref-type="table"}.

###### 

The list of 10 DFNB loci screened in this study. The corresponding genes and characteristic of screening markers are shown

  ***locus (gene)***   ***STR***   ***Heterozygosity (%)***   ***Size(bp)***   ***Forward primer***        ***Reverse primer***
  -------------------- ----------- -------------------------- ---------------- --------------------------- ---------------------------
  DFNB7--11 (*TMC1*)   D9S1876     81                         132--152         GATGTACCCAGAGAAGTCTCG       AGTGGTTACCATTTACCCAAG
                       D9S1124     76                         252--276         GGTGCCCACCATACACTACT        TCTAATCCTTCCTTCCCTCG
                       D9S301      78                         205--251         CATGATGGTGGTCTCTGG          GGTGGGGCTCAAAGAGTAG
                       D9S1799     91                         139--178         TTGCCAACTATTTTAGCCC         TGCAGTTTCAATCCACATC
  DFNB3 *(MYO15A*)     D17S953     81                         119--131         ACTATCCGCCCAATACA           AAGGGCTTGCTTTGAC
                       D17S1843    70                         177--187         TGCACAGGCCAATTCCTTAC        TGCCTAAACTGCTTTCAGGTGAG
                       D17S620     50                         103--151         CTCTTTGTGCTTGGCAGGGT        TACATTTAATGCAGGATGCC
                       D17S2196    81                         139--163         CCAACATCTAGAATTAATCAGAATC   ATATTTCAATATTGTAACCAGTCCC
  DFNB2 (*MYO7A)*      D11S4179    72                         200--256         GGATGTAAGAGTAACTGG CTCCG    GAAAATGTTCTGCCTGAGGG
                       D11S4186    79                         154--175         ATTCTCCCAATCTATCGCTC        GGGCAGTAATGATGATGTG
                       D11S4079    75                         217--265         CAGCAAGATCCTGTCTCAA         CTCCTTAAAGTGGGGGAGTT
                       D11S911     85                         159--203         CTTCTCATGCTTGACCATTT        CTTCTGAACAATTGCCACAT
  DFNB4 *(SLC26A4)*    D7S2420     81                         240--290         CCTGTATGGAGGGCAAACTA        AAATAATGACTGAGGCTCAAAACA
                       D7S496      63                         129--141         AACAACAGTCAACCCACAAT        GCTATAACCTCATAANAAACCAAAA
                       D7S2459     77                         140--152         AAGAAGTGCATTGAGACTCC        CCGCCTTAGTAAAACCC
                       D7S2456     78                         238--252         CTGGAAATTGACCTGAAACCTT      ACAGGGGTCTCTCACACATATTA
  DFNB9 (*OTOF)*       D2S365      85                         164--204         ATGATTTGTGTACCTTATGTATGTT   TCAATGGAGGAATCCTACTT
                       D2S2247     78                         130--160         TCCATCTTTTGCGTGC            CCGTGCTCTATGCCAG
                       D2S174      65                         203--221         AGGCTGAATCCCACCTCC          TTAGAGCACACATGGTCACTCC
                       D2S2223     63                         182--200         CACTGCGCCTAGCCTC            GGCGATTTATGAATAATCCTGC
  DFNB21 *(TECTA*)     D11S1774    60                         206--226         CAAAAAGGCTTGGCGGTT          GGGCATTCCCATGCTCA
                       D11S925     85                         173--195         AGAACCAAGGTCGTAAGTCCTG      TTAGACCATTATGGGGGCAA
                       D11S4089    75                         199--213         TAATCAAAGGCTGTAGTGAATTGG    ATTCCTAGTTCCCTCATAAACACTG
                       D11S4107    70                         172--212         TCATTCTACAAGACTAGCATTACC    GCTTGATCATGGTGTATTATCTT
  DFNB53 (*CO11A2l)*   D13S1236    70                         108--132         GCACTTGGCCTGGGTAA           AAGGGGCTGGCTCTTCA
                       D13S175     75                         101--113         TATTGGATACTTGAATCTGCTG      TGCATCACCTCACATAGGTTA
  DFNB59 *(PJVK)*      D2S2173     70                         201--243         GGAGACAGAGAGTTTACATTTGAG    GCCACACTTTCCTGAATC
                       D2S324      85                         264--275         TTACCCACCGGGACAGT           CAGCAAATGCTTCTAGGTCA
                       D11S1314    78                         209--227         TTGCTACGCACTCCTCTACT        GTGAAGGCAGGAAATGTGAC
  DFNB63 *(LRTOMT)*    D11S4162    75                         263--269         GTTCTCCAGAGAGACAGCAC        GAGAGCAACACTATTGCCC
                       D11S4140    72                         189--199         TGCAACAAGGTTCCACACT         CTTATGGGTGAGGGCACAG
                       D11S4184    60                         263--277         CCCAGCCTTACATATTCC          GCTGATGAGCAGAGGTAG
  DFNB24 *(RDX)*       11S1793     85                         124--140         AGTCATGCATCCTCCCTGTA        ATCCTGAACACATTCCTCAA
                       D11S1391    75                         158--178         TGCATGCATACATACATACATACA    CATCCATCCCTCTGTCTCTG
                       D11S2017    70                         109--133         TTTGAATAGGAAATTAGATGGTAGG   TTTGAATAGGAAATTAGATGGTAGG
                       D11S1893    58                         206--258         TCCCTGGAACCTGGAT            TGATGTGGGCTTTTTCAA

Genotyping STR markers and Linkage Analysis
-------------------------------------------

PCR of STR markers was conducted according to the standard procedure. The touchdown program was used for markers amplification. Thermal cycling conditions for amplifying markers were in accordance with previous protocols ([@B4]). PCR conditions were as follows: 2 μl MgCl~2~ (4 mM), 2.5 μl Taq PCR buffer (10X), 0.12 μl of each of the primers (10 PM), 0.15 μl Taq DNA polymerase (5U/ul), 0.9 μl dNTP mix (10 mM) and 1.2 μl DNA (about 70 ng). The reaction was adjusted to the volume of 25 ul by ddH~2~O. Standard cycling was done in a thermocycler (ASTEC PC-818; ASTEC, Fukouka, Japan). STR markers were selected based on their physical distance found at NCBI UniSTS. The criteria for selecting these markers are as follows: greater heterogeneity values, and lying near or at the known loci. At least 4 STR markers were selected for linkage analysis. [Table 1](#T1){ref-type="table"} summarizes the general characteristics of the markers used in the study. PCR products were loaded on 12% polyacrylamide gel, followed by silver nitrate staining. Two-point and multipoint parametric LOD scores were calculated using Superlink (ver. 1.6) and GeneHunter (ver. 2.91), respectively. Haplopainter version 029.5 software package was used for reconstruction of haplotypes ([@B12]).

Results
=======

Families and clinical data
--------------------------

After excluding mutations in the *GJB2* gene, 60 Iranian families segregating (ARNSHL), from Isfahan and Hamedan provinces (30 families from each province) in the center and west of Iran, were screened for 10 ARNSHL loci. Totally, 634 individuals were studied 245 of whom were patients, with ages ranging from 6 months to 52 yr. For 45 families, PTA was consistent with profound HL (≥80 dB), 12 families showed severe HL (61--80 dB), whereas the 3 remaining families showed moderate HL (41--60 dB).

SLINK calculation, genotyping and linkage analysis
--------------------------------------------------

Totally, 9 families were of SLINK values ≥3.2, 24 families had SLINK values of 2.5--3.2. The rest of the families presented values 1.8--2.5. Screening loci for homozygosity mapping in this study were composed of: DFNB2 (*MYO7A*), DFNB3 (*MYO15A*)*,* DFNB4 (*SLC26A4*), DFNB7/11(*TMC1*), DFNB9 (*OTOF*), DFNB21 (*TECTA*)*,* DFNB24 (*RDX*), DFNB59 (*PJVK*), DFNB63 *(LRTOMT)* and DFNB53 *(COL11A2).* The family members were individually genotyped for these markers. After genotyping of STR markers and linkage analysis, 14 out of the 60 families, negative for *GJB2* mutations, showed linkage to five different loci ([Table 2](#T2){ref-type="table"}). DFNB4 was the most frequent locus in the studied ARNSHL series in both provinces (36.9% of the etiology). Three out of 30 (10%) and 2 of 30 (6.6%) families were linked to DFNB4 in Isfahan and Hamedan provinces, respectively. DFNB2, DFNB3, and DFNB9 were ranked next after DFNB4. [Table 3](#T3){ref-type="table"} shows the linked families and the maximum values for SLINK, two-point and multipoint LOD scores. One family (3.3%) from every single province was linked to DFNB9. One family from Hamedan Province was linked to DFNB7/11 (7.7% of the etiology). The haplotypes of 3 selected linked families are shown in [Fig. 1(a--c)](#F1){ref-type="fig"}.

![Pedigree and haplotypes of the 3 Iranian families with ARNSHL, negative for *GJB2* mutations, linked to 2 known loci. a) ISF-5 is linked to DFNB4: b) IR-3 is linked to DFNB3 c) IR-14 is linked to DFNB4. Hearing impaired patients show homozygosity for markers. The order of markers is based on the Marshfield map](IJPH-48-1704-g001){#F1}

###### 

Genetic etiology of ARNSHL in 60 families negative for *GJB2* mutations from Isfahan and Hamedan provinces

  ***Number***   ***Locus***   ***Gene***   ***Number of diagnoses***   ***% of diagnoses***   ***% of cohort***                 
  -------------- ------------- ------------ --------------------------- ---------------------- ------------------- ------ ------ ------
  1              DFNB2         *MYO7A*      1                           2                      7.2                 15.4   3.3    6.6
  2              DFNB3         *MYO15A*     1                           2                      7.2                 15.4   3.3    6.6
  3              DFNB4         *SLC26A4*    3                           2                      21.5                15.4   10     6.6
  4              DFNB7-11      *TMC1*       0                           1                      0                   7.7    0      3.3
  5              DFNB9         *OTOF*       1                           1                      7.2                 7.2    3.3    3.3
  Total                                     6                           8                                                 19.9   26.4

###### 

Maximum SLINK and LOD score (two-point and multi-point) values for the linked families

  ***Number***   ***Family ID***   ***SLINK value***   ***Linked locus***   ***Two-point LOD score***   ***Multi-point LOD score***   ***Severity HL***
  -------------- ----------------- ------------------- -------------------- --------------------------- ----------------------------- -------------------
                 ISF-5             2.82                DFNB4                1.7                         2.2                           Severe-profound
  2              ISF-15            2.9                 DFNB4                2.6                         2.8                           Moderate-profound
  3              ISF-6             3.8                 DFNB4                3.1                         3.2                           Moderate-severe
  4              IR-14             3.28                DFNB4                2.4                         2.6                           Profound
  5              IR-9              1.8                 DFNB4                2.2                         2.3                           Severe-profound
  6              IR-13             2.53                DFNB2                1.9                         2.3                           Severe-profound
  7              IR-30             2.8                 DFNB2                2.3                         2.6                           Moderate-profound
  8              ISF-17            1.9                 DFNB2                2                           2.2                           Profound
  9              IR-19             3.4                 DFNB9                2.8                         3.9                           Severe-profound
  10             ISF-14            2.8                 DFNB9                1.9                         2.3                           Profound
  11             IR-3              2.3                 DFNB3                2.1                         2.4                           Profound
  12             IR-27             3.1                 DFNB3                2.9                         3.1                           Profound
  13             ISF-23            2.4                 DFNB3                2.1                         2.3                           Severe-profound
  14             IR-7              2.1                 DFNB7-11             2                           2.2                           Severe-profound

We did not find linkage to the other loci (DFNB21, DFNB24, DFNB59, DFNB63 and FNB53) among the studied families.

Discussion
==========

We determined the contribution of 10 DFNB loci to HL in 60 Iranian families affected with ARNSHL and negative for the *GJB2* mutations. We have obtained 20% and 26% involvement of *GJB2* mutations in ARNSHL in Hamedan and Isfahan provinces, respectively (unpublished data).

For the first time, we investigated the role of 10 other loci in the etiology of HL in *GJB2* negative families in the west and center of Iran. DFNB4 was found to be the mostly linked locus among the studied families, with 3 out of 30 (10%) and 2 of 30 (6.6%) showing linkage to it in Isfahan and Hamedan provinces, respectively.

Mutations in its corresponding gene (i.e. *SLC26A4*) are the second most common cause of ARNSHL, after *GJB2*, all over the world ([@B13]). About 5% of ARNSHL cases in South Asia have been related to *SLC26A4* mutations ([@B14]). Variants in this gene can cause both ARNSHL at the DFNB4 locus and Pendred Syndrome (PS), known as one of the most common forms of syndromic HL. PS is correlated to hypothyroidism (goiter) later in life. Present data show no sign of PS in the studied families. Several reports have revealed *SLC26A4* mutations in ARNSHL in Iranian populations. In a study, 12 families out of 80 (15%) Iranian families with 2 or more ARNSHL patients were linked to DFNB4 locus ([@B15]). In a recent study 12 out of 121 (9.9%) families were linked to DFNB4 ([@B16]). Thus, our result shows that DFNB4 contributes mainly to ARNSHL in the west and center of Iran and is ranked second after DFNB1, which is in agreement with previous studies reported from Iran ([Table 4](#T4){ref-type="table"}). The next most frequently linked locus in our cohort was DFNB2, which accounts for about 6.6% of HL etiology in Hamedan and 3.3% in Isfahan. The related gene *MYO7A*, encoding myosin VIIA, is an action-based molecular motor converting energy from ATP hydrolysis into mechanical force. It also interacts with actin to participate in the formation of the mechanotransduction complex, which is critical for detecting sound ([@B17]).

###### 

The overview of DFNB loci frequencies obtained from in the studies on the Iranian ARNSHL patients

  ***Loci***   ***Number of cases***   ***Number of affected***   ***Frequency (%)***   ***References***
  ------------ ----------------------- -------------------------- --------------------- ------------------
  DFNB2        144                     4                          2.77                  Babanejad et al.
  302          15                      4.96                       Heggen et al.         
  60           3                       5                          This study            
  DFNB3        144                     8                          5.5                   Babanejad et al.
  302          29                      9.6                        Heggen et al.         
  60           3                       5                          This study            
  DFNB4        80                      12                         15                    Kahrizi et al.
  302          37                      12.25                      Heggen et al.         
  60           5                       8.3                        This study            
  DFNB7-11     144                     4                          2.7                   Babanejad et al.
  54           1                       2.2                        Dahaghani et al.      
  60           1                       1.66                       This study            
  DFNB9        144                     1                          0.69                  Babanejad et al.
  38           1                       2.38                       Mahdieh et al.        
  60           2                       3.3                        This study            

DFNB2-linked families have been reported from Iran ([@B18]). 2.8% of DFNB2 involvement in ARNSHL etiology were reported in the studied Iranian cohort ([@B19]). Similarly, Sloan-Heggen et al. ([@B20]) using a custom targeted genomic enrichment method in a cohort of 302 *GJB2-*negative Iranian families, found the DFNB2 contribution to be 5%, which is in accordance with our results ([Table 4](#T4){ref-type="table"}).

Our data show that one out of 30 families (3.3%) from Isfahan province and two out of 30 families (6.6%) from Hamedan were linked to DFNB3. The DFNB3 locus was first identified in the village of Indonesia, Bengkala, with a frequency of 9.4% among the inbred population ([@B21]). Since then, many mutations have been reported from different countries such as India, Iran, Turkey, and Brazil ([@B22], [@B23]). In Pakistan, DFNB3 is the third locus for ARNSHL accounting for 5% of ARNSHL ([@B24]). In a previous study on 40 Iranian ARNSHL families from Qom and Markazi provinces, from center of Iran, 2 families were linked to DFNB3 (5.8%) ([@B25]). Therefore, the locus could be one common cause of ARNSHL both in the west and center of Iran.

In the present study, one family (3.3%) from every single province was linked to DFNB9 *(OTOF)*. Mutations in the *OTOF* gene (named as homology to Ferlin (Fer-1)) encoding otoferlin at DFNB9 results in ARNSHL which is sometimes associated with auditory neuropathy. Otoferlin is a member of the ferlin protein family; its role is in vesicle recycling and efficient and linear encoding of low-intensity stimulate the synapse between inner hair cells and auditory nerve fibers ([@B26]). *OTOF* mutations have been reported from many countries such as Pakistan, Spain, Italy, and Japan with different mutation spectrum ([@B26], [@B27]). The frequency of the *OTOF* gene mutations has been reported to be 2.7% in Iran ([@B28]). It was screened 37 Iranian ARNSHL families from 7 different provinces for 15 loci using linkage analysis and found 1 family (2.7%) to be linked to the DFNB9 locus. Similarly, in our present study, one family (3.3%) from each of the two provinces was linked to DFNB9 *(OTOF)*.

Our study involves 3 families with moderate to severe HL highlighted by a "U" shaped audiogram. DFNB21 and DFNB93 are related to this audio profile ([@B18], [@B29]). Interestingly, none of the 3 families was linked to DFNB21. Thus, the next step for these families involves investigating the DFNB93 contribution ([@B30]).

The contribution of DFNB7/11 in Hamedan Province was found to be 3.3% (1/30), in line with the prevalence figures of 4% in Pakistan, and 3.4% in Turkey. The related gene *TMC1* (Transmembrane channel-like gene I) is required for postnatal hair cell development. *TMC1* might be an ion channel or transporter which mediates K^+^ homeostasis in the inner ear ([@B31]). The *TMC1* gene was initially mapped to chromosome 9q13--q21 in two consanguineous Indian families with prelingual, severe-to-profound defining the DFNB7/11 locus (NM_138691.2). In the study on 144 *GJB2*-negative subjects, using linkage analysis and direct sequencing, 4 out of 144 families (2.7%) were linked to DFNB7-11([@B19]). Moreover, Dehaghani et al. ([@B32]), using homozygosity mapping on 45 ARNSHL families, detected 1family (2.2%) to be linked to DFNB7/11. Therefore, the locus could be one common causes of ARNSHL in the west of Iran.

The next step of the study involves DNA sequencing of the corresponding genes of the DFNB loci in the linked families to identify the pathogenic mutations. Until now, 4 homozygous mutations have been identified in the related families, including 3 missense and 1 splice site mutations ([@B7], [@B33]). The identified mutations and their characteristics are listed in [Table 5](#T5){ref-type="table"}. The large size of some of the related genes hinders detection of their related mutations ([@B34]). However, the remaining families have been considered for sequencing of the related genes.

###### 

The mutations detected in the linked families in this study

  ***Number***   ***Family ID***   ***Gene***   ***Type of mutation***   ***Nucleotide change***   ***Amino acid change***
  -------------- ----------------- ------------ ------------------------ ------------------------- -------------------------
  1              IR-14             *SLC26A4*    missense                 c.416 G\>T                p.Gly139Val
  2              ISF-5             *SLC26A4*    Splice site              c.919-2 A\>G              \-
  3              IR-27             *MYO15A*     missense                 c.6442 T\>A               p.Trp2148Arg
  4              IR-13             *MYO7A*      missense                 c.6487 G\>A               p.Gly2163Ser

In the present study, despite the high heterogeneity of ARNSHL, we could detect the genetic etiology in 6 out of 30 (20%) and 8 out of 30 (26.6%) ARNSHL families, negative for *GJB2* mutations, from Isfahan and Hamedan provinces, respectively. Thus, nearly 23.5% of ARNSHL families negative for *GJB2* mutations are linked to 5 loci including DFNB4, DFNB2, DFNB3, DFNB9 and DFNB7/11. The remaining genes and loci could be either rare or yet to be identified ([@B2], [@B28]). The study is in progress by subjecting some of the remaining families to the next-generation sequencing, which is a rapid and cost-effect method.

Conclusion
==========

Using homozygosity mapping, we detected 23.5% of the genetic etiology of *GJB2-* mutation negative ARNSHL in Isfahan and Hamedan provinces. This finding is interesting in view of the extreme genetic heterogeneity of ARNSHL (with over 50 genes discovered so far). Investigation of a limited number of genes could lead to an acceptable level of diagnostic yield.
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